Radiopharm Theranostics Files 6-K Report
Ticker: RDPTF · Form: 6-K · Filed: Nov 18, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Nov 18, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, sec-compliance
TL;DR
Radiopharm Theranostics files routine 6-K, confirms 20-F annual reports.
AI Summary
Radiopharm Theranostics Limited, a foreign private issuer, filed a Form 6-K on November 18, 2025. The filing indicates the company is subject to reporting requirements under the Securities Exchange Act of 1934 and will file annual reports under Form 20-F. The company's principal executive office is located in Carlton South, Victoria, Australia.
Why It Matters
This filing is a routine report for foreign private issuers, providing an update on their regulatory compliance and reporting status with the SEC.
Risk Assessment
Risk Level: low — This is a standard regulatory filing for a foreign private issuer and does not contain new financial or operational information.
Key Players & Entities
- Radiopharm Theranostics Limited (company) — Registrant
- 001-41621 (company) — Commission File Number
- 20251118 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Form
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the registrant makes public, is required to make public, or is required by a stock exchange to publish or file in its home country.
What is the Commission File Number for Radiopharm Theranostics Limited?
The Commission File Number for Radiopharm Theranostics Limited is 001-41621.
What type of annual report does Radiopharm Theranostics Limited file?
Radiopharm Theranostics Limited files its annual reports under cover of Form 20-F.
Where is Radiopharm Theranostics Limited's principal executive office located?
Radiopharm Theranostics Limited's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
On what date was this Form 6-K filed?
This Form 6-K was filed on November 18, 2025.
Filing Stats: 323 words · 1 min read · ~1 pages · Grade level 19 · Accepted 2025-11-18 06:07:09
Filing Documents
- ea0266143-6k_radio.htm (6-K) — 13KB
- ea026614301ex99-1_radio.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-25-111746.txt ( ) — 30KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on November 18, 2025 titled: “RAD Approval for Phase 1 Therapeutic Trial of RAD 402” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 RAD Approval for Phase 1 Therapeutic Trial of RAD 402 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: November 18, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3